Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2023	$ 981,329	$ 816	$ 2,169,798	$ 604	$ (1,189,889)
Beginning Balance, Shares at Dec. 31, 2023		81,632,496
Purchase of common stock under ESPP	1,398	$ 1	1,397
Purchase of common stock under ESPP, Shares		76,461
Vesting of restricted common stock		$ 4	(4)
Vesting of restricted common stock, Shares		420,579
Stock-based compensation	29,281		29,281
Exercise of common stock options	1,676	$ 2	1,674
Exercise of common stock options, Shares		151,291
Other comprehensive income (loss)	(1,525)			(1,525)
Net loss	(98,669)				(98,669)
Ending Balance at Mar. 31, 2024	913,490	$ 823	2,202,146	(921)	(1,288,558)
Ending Balance, Shares at Mar. 31, 2024		82,280,827
Beginning Balance at Dec. 31, 2023	981,329	$ 816	2,169,798	604	(1,189,889)
Beginning Balance, Shares at Dec. 31, 2023		81,632,496
Net loss	(189,720)
Ending Balance at Jun. 30, 2024	854,094	$ 824	2,233,989	(1,110)	(1,379,609)
Ending Balance, Shares at Jun. 30, 2024		82,386,210
Beginning Balance at Mar. 31, 2024	913,490	$ 823	2,202,146	(921)	(1,288,558)
Beginning Balance, Shares at Mar. 31, 2024		82,280,827
Vesting of restricted common stock		$ 1	(1)
Vesting of restricted common stock, Shares		72,040
Stock-based compensation	31,604		31,604
Exercise of common stock options	240		240
Exercise of common stock options, Shares		33,343
Other comprehensive income (loss)	(189)			(189)
Net loss	(91,051)				(91,051)
Ending Balance at Jun. 30, 2024	854,094	$ 824	2,233,989	(1,110)	(1,379,609)
Ending Balance, Shares at Jun. 30, 2024		82,386,210
Beginning Balance at Dec. 31, 2024	733,545	$ 836	2,298,661	679	(1,566,631)
Beginning Balance, Shares at Dec. 31, 2024		83,633,069
Purchase of common stock under ESPP	1,501	$ 1	1,500
Purchase of common stock under ESPP, Shares		90,436
Issuance of common stock and pre-funded warrants, net of issuance costs	470,478	$ 162	470,316
Issuance of common stock and pre-funded warrants, net of issuance costs, Shares		16,151,686
Vesting of restricted common stock		$ 6	(6)
Vesting of restricted common stock, Shares		607,196
Stock-based compensation	26,682		26,682
Exercise of common stock options	719	$ 1	718
Exercise of common stock options, Shares		74,707
Other comprehensive income (loss)	(519)			(519)
Net loss	(109,270)				(109,270)
Ending Balance at Mar. 31, 2025	1,123,136	$ 1,006	2,797,871	160	(1,675,901)
Ending Balance, Shares at Mar. 31, 2025		100,557,094
Beginning Balance at Dec. 31, 2024	$ 733,545	$ 836	2,298,661	679	(1,566,631)
Beginning Balance, Shares at Dec. 31, 2024		83,633,069
Exercise of common stock options, Shares	195,198
Net loss	$ (211,561)
Ending Balance at Jun. 30, 2025	1,046,813	$ 1,008	2,823,987	10	(1,778,192)
Ending Balance, Shares at Jun. 30, 2025		100,758,748
Beginning Balance at Mar. 31, 2025	1,123,136	$ 1,006	2,797,871	160	(1,675,901)
Beginning Balance, Shares at Mar. 31, 2025		100,557,094
Issuance of common stock and pre-funded warrants, net of issuance costs	(4)		(4)
Vesting of restricted common stock		$ 1	(1)
Vesting of restricted common stock, Shares		81,163
Stock-based compensation	24,367		24,367
Exercise of common stock options	1,755	$ 1	1,754
Exercise of common stock options, Shares		120,491
Other comprehensive income (loss)	(150)			(150)
Net loss	(102,291)				(102,291)
Ending Balance at Jun. 30, 2025	$ 1,046,813	$ 1,008	$ 2,823,987	$ 10	$ (1,778,192)
Ending Balance, Shares at Jun. 30, 2025		100,758,748

Beam Therapeutics Inc. 10-Q